ELDNEledon Pharmaceuticals Inc
$3.78
$0.175
(4.43%)
EarningsAug 13
Mkt Cap$304.89M
Vol418,383.00
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up PR Newswire LAS VEGAS, July 21, 2026 Issued on behalf of Ava Bio, Inc. (OTCQB: AVAI)LAS...
PR Newswire
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy PR Newswire LAS VEGAS, July...
PR Newswire
Natera and Eledon Announce Strategic Partnership for Prospera Monitoring in Planned Phase 3 Kidney Transplant Trial
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a...
Business Wire
Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?
Here is how Eledon Pharmaceuticals, Inc. (ELDN) and Galderma Group AG - Unsponsored ADR (GALDY) have performed compared to their sector so far this year.
Zacks
Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?
Here is how BillionToOne (BLLN) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.
Zacks
Eledon Pharmaceuticals (ELDN) Expected to Announce Earnings on Wednesday
Eledon Pharmaceuticals (NASDAQ:ELDN) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-13-eledon-pharmaceuticals-inc-stock...
MarketBeat
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Recommendation of "Hold" from Analysts
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) has been assigned a consensus recommendation of "Hold" from the five ratings firms that are covering the firm, Marketbeat reports. One...
MarketBeat
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Down 14.5% in March
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totaling 7,193,953...
MarketBeat
SG Americas Securities LLC Makes New Investment in Eledon Pharmaceuticals, Inc. $ELDN
SG Americas Securities LLC bought a new position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and...
MarketBeat
Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines
Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines PR Newswire VANCOUVER, BC, April 6, 2026 Issued on behalf...
PR Newswire
<
1
2
...
>
Advertisement|Remove ads.
Latest ELDN News
ViewA Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
PR Newswire
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy
PR Newswire
Natera and Eledon Announce Strategic Partnership for Prospera Monitoring in Planned Phase 3 Kidney Transplant Trial
Business Wire
SMCI4
8
RKLB2
3
RDDT3
9Advertisement|Remove ads.